retatrutide clinical trials safety efficacy Today, we shared new data from two Phase 3 of retatrutide, our investigational triple agonist. Learn more at our link in bio Retatrutide, an Amazing Future for

This product is not intended to diagnose, treat, cure, or prevent any disease.

While tirzepatide and retatrutide share the common goal of weight loss and improving metabolic health, the unique triple-hormone receptor agonism of retatrutide sets it apart, offering the potential for more significant weight loss and sustained weight reduction

This can allow companies to focus on areas of highest risk as they continually assess and improve their internal procedures and processes

Total annual cost: $1,500 to $4,500 in filler maintenance plus $200 to $300 in at-home consumables

As with all incretin-based therapies, retatrutide's side effect profile is closely linked to its receptor pharmacology